EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Improving CDK4/6 inhibitors adherence in breast cancer using the CONnected CUstomized Treatment Platform (CONCURxP) mobile health intervention: Study protocol for ECOG-ACRIN EAQ221CD

Gelareh Sadigh, Fenghai Duan, Ilana F Gareen, Judy Hancock, JoRean D Sicks, Maryanne Thangarajah, Jane L Meisel, Mylin A Torres, Scott D Ramsey, Antonio C Wolff, Lynne I Wagner, Ruth C Carlos und 1 weitere

Contemporary Clinical Trials · 2026

DOI: 10.1016/j.cct.2025.108145 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Contemporary Clinical Trials, 2026. Verfasst von Gelareh Sadigh und 12 weiteren Autor:innen. Beteiligte Einrichtung: Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA, United States of America. Electronic address: gsadigh@uci.edu. Hauptthemen laut MEDLINE: Breast Neoplasms, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cyclin-dependent kinase 4/6 inhibitors (CDKIs) improves survival when added to endocrine therapy in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. However, their complex schedule, side effects, and cost contribute to non-adherence. METHODS: The EAQ221CD is a two-arm randomized controlled trial that evaluates the effectiveness of the CONnected CUstomized Treatment Platform (CONCURxP), a mobile health intervention, versus enhanced usual care (EUC) on CDKI adherence among 390 patients with breast cancer and a new CDKI prescription. Participants use a smart pouch (Wisebag) to monitor real-time adherence. CONCURxP arm patients: (1) receive text reminders for missed or extra doses; (2) receive text message surveys inquiring reasons for missed or extra doses; and (3) have access to their adherence history on a study web portal. Missed or double doses trigger alerts to the oncology team. Patients citing cost as a barrier are referred to a national non-profit financial navigation program. EUC arm patients receive educational materials on side effect management. Patients complete surveys at baseline, 3, 6, and 12 months after randomization. Our objectives are to: (1) compare 12-month CDKI adherence measured using Wisebag (primary outcome) between the two arms; (2) compare patient-reported outcomes at 12-months between the two arms, including symptom burden, quality of life, patient-provider communication, self-efficacy for managing symptoms, and financial worry; and (3) use mixed methods to describe patients' experience with the CONCURxP intervention. Our multilevel intervention will provide actionable results to improve adherence, health outcomes, and patients' experience. TRIAL REGISTRATION: NCT06112613.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsProtein Kinase InhibitorsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Medication AdherenceHumansFemaleText MessagingTelemedicineRandomized Controlled Trials as TopicReminder SystemsQuality of Life

Stichwörter der Autor:innen

Breast cancerMedication adherenceMobile healthRemote monitoring

Substanzen

Protein Kinase InhibitorsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6CDK4 protein, human

Autor:innen und Institutionen

  • Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA, United States of America. Electronic address: gsadigh@uci.edu.
  • Brown University - ECOG-ACRIN Biostatistics Center, Providence, RI, United States of America.
  • Brown University - ECOG-ACRIN Biostatistics Center, Providence, RI, United States of America; Brown University School of Public Health Department of Epidemiology, Providence, RI, United States of America.
  • Cancer Research for the Ozarks NCORP, Springfield, MO, United States of America.
  • Winship Cancer Institute, Emory University, Atlanta, GA, United States of America.
  • Hutchinson Institute for Cancer Outcomes Research, Seattle, WA, United States of America.

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • National Cancer Institute
  • Pfizer

Zitieren

APA

Sadigh, G., Duan, F., Gareen, I. F., Hancock, J., Sicks, J. D., Thangarajah, M., Meisel, J. L., Torres, M. A., Ramsey, S. D., Wolff, A. C., Wagner, L. I., Carlos, R. C., & Graetz, I. (2026). Improving CDK4/6 inhibitors adherence in breast cancer using the CONnected CUstomized Treatment Platform (CONCURxP) mobile health intervention: Study protocol for ECOG-ACRIN EAQ221CD. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2025.108145

Vancouver

Sadigh G, Duan F, Gareen IF, Hancock J, Sicks JD, Thangarajah M, et al. Improving CDK4/6 inhibitors adherence in breast cancer using the CONnected CUstomized Treatment Platform (CONCURxP) mobile health intervention: Study protocol for ECOG-ACRIN EAQ221CD. Contemporary Clinical Trials. 2026. doi:10.1016/j.cct.2025.108145

BibTeX
@article{Sadigh2026,
  author = {Sadigh, Gelareh and Duan, Fenghai and Gareen, Ilana F and Hancock, Judy and Sicks, JoRean D and Thangarajah, Maryanne and Meisel, Jane L and Torres, Mylin A and Ramsey, Scott D and Wolff, Antonio C and Wagner, Lynne I and Carlos, Ruth C and Graetz, Ilana},
  title = {Improving CDK4/6 inhibitors adherence in breast cancer using the CONnected CUstomized Treatment Platform (CONCURxP) mobile health intervention: Study protocol for ECOG-ACRIN EAQ221CD},
  journal = {Contemporary Clinical Trials},
  year = {2026},
  doi = {10.1016/j.cct.2025.108145}
}
Kostenlos starten →